Atlas Molecular Pharma closes a €3 million funding round led by Inveready to advance its clinical program in rare diseases

by Inveready Asset Management

The round was led by Inveready, with participation from CDTI, Grupo SPRI, Kereon Partners, Endometrial DIDI, and CRB Inverbio. This funding will enable the company to carry out a Phase I–II clinical...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Xcalibur Smart Mapping strengthens its g...

by MCH Private Equity

​Xcalibur Smart Mapping, recognised as the global leader in airborne...

Photos Stream